NCT05880108

Brief Summary

The research in this VA Merit will examine the effects of obesity and Post-COVID Conditions (PCC) on physical functioning, health-related quality of life, and adipose tissue inflammatory and cellular senescence profiles in older Veterans. Further, it will evaluate whether a weight loss intervention, including dietary modification and exercise, in obese Veterans with and without PCC will reduce systemic and adipose tissue inflammation and senescence and promote PCC recovery.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P75+ for not_applicable

Timeline
30mo left

Started Jun 2024

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress45%
Jun 2024Sep 2028

First Submitted

Initial submission to the registry

May 25, 2023

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 30, 2023

Completed
1 year until next milestone

Study Start

First participant enrolled

June 3, 2024

Completed
4.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 30, 2028

Last Updated

June 29, 2025

Status Verified

June 1, 2025

Enrollment Period

4.3 years

First QC Date

May 25, 2023

Last Update Submit

June 25, 2025

Conditions

Keywords

COVID-19ObesitySenescenceWeight LossExercise

Outcome Measures

Primary Outcomes (1)

  • Cardiorespiratory Fitness (VO2max)

    VO2max (ml/kg/min) comparison between lean PCC naïve, lean with PCC, obese PCC naïve, and obese with PCC

    Baseline

Secondary Outcomes (2)

  • Change in Cardiorespiratory Fitness (VO2max)

    Baseline, After 12 weeks of Weight Loss

  • Change in adipose tissue cellular senescence

    Baseline, After 12 weeks of Weight Loss

Study Arms (2)

Weight Loss

EXPERIMENTAL

Participants will be asked to participate in a 1x/week center-based or tele-health nutrition diet class, 2x/week center-based exercise classes, and 1x/week exercise session conducted on their own for approximately 12 weeks.

Behavioral: 12-weeks of Weight Loss

Weight Stability

ACTIVE COMPARATOR

Participants will be asked to participate in a 1x/week center-based or tele-health education class, 2x/week center-based or tele-health stretching/balance classes, and 1x/week stretching/balance session conducted on their own for approximately 12 weeks.

Behavioral: 12-weeks of Weight Stability

Interventions

Participants will be asked to participate in a 1x/week center-based or tele-health nutrition diet class, 2x/week center-based exercise classes, and 1x/week exercise session conducted on their own for \~12 weeks.

Weight Loss

Participants will be asked to participate in a 1x/week center-based or tele-health education class, 2x/week center-based stretching/balance classes, and 1x/week stretching/balance session conducted on their own for \~12 weeks.

Weight Stability

Eligibility Criteria

AgeUp to 80 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • U.S. Veteran
  • Self-reported COVID-19 naïve or COVID-19 \> 90 days ago for lean and obese PCC naïve or documented COVID-19 for the lean and obese PCC groups (At least one PCC symptom \>4 weeks)
  • Body Mass Index: 19-25 or 30-50 kg/m2

You may not qualify if:

  • Neurologic, musculoskeletal, or other condition that limits subject's ability to complete study physical assessments
  • Active inflammatory, COVID-19, autoimmune, infectious, hepatic (LFTs \> 2.5 x WNL), renal (eGFR\<45), gastrointestinal, malignant, and psychiatric disease
  • Uncontrolled diabetes (HbA1c \>10% or the current use of insulin)
  • Weight change within the past month of \>5 kg
  • Self-reported alcohol or drug abuse
  • Anti-coagulant medication usage

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD

Baltimore, Maryland, 21201, United States

RECRUITING

South Texas Health Care System, San Antonio, TX

San Antonio, Texas, 78229-4404, United States

RECRUITING

MeSH Terms

Conditions

Post-Acute COVID-19 SyndromeObesityCOVID-19Weight LossMotor Activity

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract DiseasesPost-Infectious DisordersChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsOverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsBody Weight ChangesBehavior

Study Officials

  • Alice S. Ryan, PhD

    Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Kristina Marcus, MS

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Outcome assessors will be blinded to treatment allocation/group assignment
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Weight Loss Program (Diet and Exercise)
Sponsor Type
FED
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 25, 2023

First Posted

May 30, 2023

Study Start

June 3, 2024

Primary Completion (Estimated)

September 30, 2028

Study Completion (Estimated)

September 30, 2028

Last Updated

June 29, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share

Locations